SARS-CoV-2 mutational variants may represent a new challenge to society, but not to the virucidal armamentarium
J Hosp Infect
.
2021 Jun:112:121-123.
doi: 10.1016/j.jhin.2021.03.013.
Epub 2021 Mar 22.
Authors
M K Ijaz
1
,
R W Nims
2
,
J McKinney
3
Affiliations
1
Global Research & Development for Lysol and Dettol, Reckitt Benckiser LLC, Montvale, NJ, USA. Electronic address: Khalid.Ijaz@rb.com.
2
RMC Pharmaceutical Solutions, Inc., Longmont, CO, USA.
3
Global Research & Development for Lysol and Dettol, Reckitt Benckiser LLC, Montvale, NJ, USA.
PMID:
33766545
PMCID:
PMC7983357
DOI:
10.1016/j.jhin.2021.03.013
No abstract available
Publication types
Letter
Comment
MeSH terms
Antiviral Agents
COVID-19*
Humans
SARS-CoV-2*
Substances
Antiviral Agents